Li Zhou
- Cancer Research top 2%
- MicroRNA in disease regulation 12
- Protease and Inhibitor Mechanisms 11
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis 14
- Oncology top 5%
- Pancreatic and Hepatic Oncology Research 36
- Peptidase Inhibition and Analysis 15
- Cancer-related Molecular Pathways 10
- Molecular Biology top 5%
- Epigenetics and DNA Methylation 10
- Immunology top 10%
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 15
- Cited by
- Cancer ResearchHepatologyOncology
- Partner nations
- ChinaUnited KingdomUnited States
In The Last Decade
Li Zhou
114 papers receiving 2.7k citations
Peers
Comparison fields: 5 of 107
- Cancer Research 1.0k
- Hepatology 293
- Oncology 905
- Molecular Biology 1.5k
- Immunology 314
Countries citing papers authored by Li Zhou
This map shows the geographic impact of Li Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li Zhou more than expected).
Fields of papers citing papers by Li Zhou
This network shows the impact of papers produced by Li Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li Zhou. The network helps show where Li Zhou may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Li Zhou, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 3 | |
| 4 | 2024 | 3 | |
| 5 | 2024 | 3 | |
| 6 | 2020 | 17 | |
| 7 | 2017 | 81 | |
| 8 | Concordance of immunohistochemistry and fluorescent in situ hybridization for anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer: Results from a multicenter study in China | 2016 | 1 |
| 9 | 2016 | 34 | |
| 10 | 2015 | 50 | |
| 11 | 2015 | 17 | |
| 12 | 2015 | 69 | |
| 13 | 2015 | 30 | |
| 14 | 2015 | 24 | |
| 15 | 2014 | 18 | |
| 16 | 2013 | 15 | |
| 17 | 2012 | 37 | |
| 18 | 2011 | 123 | |
| 19 | 2003 | 1 | |
| 20 | 2000 | 34 |
About Li Zhou
Li Zhou is a scholar working on Cancer Research, Oncology and Hepatology, having authored 118 papers that have together received 2.7k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (36 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (15 papers), Peptidase Inhibition and Analysis (15 papers), Hepatocellular Carcinoma Treatment and Prognosis (14 papers), MicroRNA in disease regulation (12 papers), Protease and Inhibitor Mechanisms (11 papers), Cancer-related Molecular Pathways (10 papers) and Epigenetics and DNA Methylation (10 papers). The work is most often cited by research in Cancer Research (1.0k citations), Hepatology (293 citations) and Oncology (905 citations). Li Zhou has collaborated with scholars based in China, United Kingdom and United States. Frequent co-authors include Yupei Zhao, Taiping Zhang, Lei You, Jing‐An Rui, Weixun Zhou, Qiang Qu, Junchao Guo, Shuguang Chen, Quancai Cui and Zhiyong Liang. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.